| Hint | Drug | Class of Drug |
|---|
| Long half-life, ~40 hours allowing a single daily dose | |
| Combination of Diclofenac and Misoprostol that provides gastric protection | |
| Anti-inflammatory and immunosuppressive actions; provide relief until other, slower acting antirheumatic drugs take effect | |
| Oral pyrimidine synthesis inhibitor; slows progression of mild rheumatoid arthritis | |
| Depletes B cells, leads to decreased cytokines and B/T cell interactions | |
| Used for rheumatoid arthritis, mild to moderate ulcerative colitis, and Crohn’s disease | |
| Inhibits binding of TNF-alpha with its receptors; used in RA and Crohn’s disease | |
| Monoclonal antibody against the IL-6 receptor | |
| Can reduce the renal excretion of lithium; ~50 hour half life, allowing single daily dose | |
| Competitively inhibits IL-1 binding to the IL-1 receptor; indicated for moderate to severe RA patients who have failed 1 or more DMARDs | |
| Covalently modifies COX-1 and COX-2, irreversibly inhibiting cyclooxygenase activity; can result in Reyes Syndrome in children | |
| Decrease TNF-alpha levels; indicated for rheumatoid arthritis in patients with inadequate response to other DMARDs | |
| Doses up to 3200 mg/day for rheumatoid arthritis; half-life in plasma is about 2 hours | |
| | Hint | Drug | Class of Drug |
|---|
| More selective COX-2 inhibitor, though it will also inhibit COX-1; side effects similar to other NSAIDs although may have lower GI effects | |
| Half-life around 14 hr allows twice a day dosing | |
| Antimalarial, second line for mild rheumatoid arthritis | |
| Weak anti-inflamatory effects; hepatic toxicity; no gastric irritation or bleeding; no effects on platelets | |
| Once the primary form of rheumatoid arthritis therapy; produces a gradual reduction of the symptoms of inflammation, does not cure | |
| Inhibits T cell activation, diminishes inflammatory cytokine and TNF secretion | |
| Recently approved TNF inhibitor | |
| Does not affect COX-1; used for osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrheal; potential cardiovascular problems | |
| Short term use for severe pain; approved for parenteral administration; topically useful for inflammation in the eye following surgery or seasonal allergies | |
| More potent cyclooxygenase inhibitor than indomethacin and naproxen; used for rheumatoid arthritis, osteoarthritis, etc | |
| One of the more potent COX inhibitors; use for treatment of arthritis and gout; GI irritation common; can cause renal dysfunction | |
| Very commonly used for rheumatoid arthritis; DHFR inhibitor; immunosuppressive | |
| Clears soluble and membrane bound TNF | |
|
Periodic Table
Multiplication Table
Minute Math (Addition)
